Onconova Therapeutics (NASDAQ:ONTX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Onconova Therapeutics (NASDAQ:ONTX) in a research note released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Onconova Therapeutics Stock Performance

Onconova Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.45. The stock has a market cap of $20.90 million, a PE ratio of -1.09 and a beta of 1.38. The company’s 50-day simple moving average is $0.84 and its 200-day simple moving average is $0.74.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer.